GliaPharm
GliaPharm is a Swiss clinical-stage biotechnology company developing glial-cell-targeting drugs for neurological and psychiatric disorders, using its proprietary GliaX™ discovery platform and lead candidate GP-119 in Alzheimer's disease.
- Company typePrivate
- Founded2016
- HeadquartersGeneva, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingServices
What GliaPharm does
GliaPharm SA is a privately held, clinical-stage Swiss biotechnology company founded in 2016 as a spinoff from Prof. Pierre Magistretti's laboratory at EPFL, headquartered at Campus Biotech in Geneva. The company develops an entirely new class of medicines that target glial cells — particularly astrocytes — and the Astrocyte-Neuron Lactate Shuttle (ANLS), seeking to restore deficient brain energy metabolism in neurological and psychiatric disorders. Its lead drug candidate, GP-119, is being advanced through IND-enabling studies for Alzheimer's disease, with additional pipeline concepts directed at GLUT1-DS (an orphan neurometabolic disease), ALS, and major depression.
GliaPharm's core technology is the proprietary GliaX™ drug discovery platform, which combines specialized glial assays, iPSC-derived brain organoids with microelectrode array (MEA) readout, digital holographic microscopy for dynamic astrocyte imaging, and AI-assisted target modeling. The platform is used internally to characterize targets and nominate candidates, and is offered for partner research. The company maintains a deep publication record (250+ peer-reviewed papers in outlets including Nature Metabolism, PNAS, Cell, Nature Neuroscience and Frontiers in Neuroscience) and is backed by an experienced operating team drawn from Serono, Astex, Eli Lilly, Idorsia, Actelion, Roche and Merck Serono.
The company is pre-revenue. Its financing to date is grant and non-dilutive capital (totaling roughly $6.4M disclosed, including a $4.2M ADDF investment in December 2023, ~$2.07M from Gliaven in 2020, and a ~$104K FONGIT award in 2022, plus Innosuisse, BRAINS, HEPIA and MassChallenge support). The intended go-to-market model is to advance GP-119 and follow-on candidates through clinical development and then monetize via licensing deals or acquisition by larger pharmaceutical companies — a biotech exits-of-IP trajectory rather than a direct commercial launch. Operations remain sub-10 employees with headquarters-only European footprint.
GliaPharm firmographics
Firmographics- Name
- GliaPharm
- Legal name
- GliaPharm SA
- Website
- https://gliapharm.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- GliaPharm is a Swiss clinical-stage biotechnology company developing glial-cell-targeting drugs for neurological and psychiatric disorders, using its proprietary GliaX™ discovery platform and lead candidate GP-119 in Alzheimer's disease.
- Ownership category
- akta.pro rank
GliaPharm industry classification
Industry- Product category
- Biopharmaceuticals — CNS / Neurology Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Translational Medicine & Biomarkers (HLAIALAF), Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)
Keywords
Where GliaPharm is headquartered
LocationHeadquarters
- HQ city
- Geneva
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
GliaPharm business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development & Licensing: Pre-revenue biopharmaceutical company developing novel drugs targeting glial cell metabolic pathways. Expected revenue model involves licensing deals or acquisition by larger pharmaceutical companies upon successful clinical development of drug candidates such as GP-119.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
GliaPharm product offering
Product offeringCore offering
GliaPharm is a clinical-stage biopharmaceutical company that discovers and develops novel drugs targeting glial cell pathways — specifically astrocytes and the Astrocyte-Neuron Lactate Shuttle (ANLS) — to treat neurological and psychiatric disorders characterized by deficient brain energy metabolism. Its lead drug candidate GP-119 is being advanced through IND-enabling studies for Alzheimer's disease, while its proprietary GliaX™ drug discovery platform identifies additional molecular targets and drug candidates across Alzheimer's, GLUT1 deficiency syndrome, ALS, and major depression.
Product overview
GliaPharm is a biotechnology company developing an entirely new class of medicines targeting glial cells for brain health. The company operates with its proprietary GliaX™ discovery platform for identifying drug candidates that impact glial cell pathways, combined with its lead drug candidate GP-119 for Alzheimer's disease. GP-119 works by targeting metabolic pathways in astrocytes to increase brain energy availability, with potential applications across multiple neurological conditions characterized by deficient brain energetics.
Differentiator
Problem solved
Functional benefit
Brands
- GliaX™: Proprietary drug discovery platform to identify and characterize molecular targets and novel drug candidates that impact glial cell pathways. Used for drug discovery and to help academic and industry partners with research.
Products and services
- GliaX™ Drug Discovery Platform Proprietary drug discovery platform used to identify and characterize molecular targets and novel drug candidates that impact glial cell pathways. Features specialized glial assays, cellular systems (primary brain cells, human iPSCs, brain organoids with microelectrode arrays), digital holographic microscopy, in vivo translational models, and AI-driven target modeling. Used for internal drug discovery and for partner research.
- GP-119 Lead drug candidate for Alzheimer's disease that targets metabolic pathways in astrocytes to increase the energy available to the brain, supporting neuroprotection and cognitive function in disorders characterized by deficient brain energetics. Currently in IND-enabling studies with intended first indication in Alzheimer's disease.
Companies that use GliaPharm
Customer profileSegments4 records
Ideal customer profiles3 records
GliaPharm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
GliaPharm partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, major and minor.
- UMC UtrechtcoreCollaboration under the GLIODEM BRAINS project focused on studying glial cell behavior in neurological disorders. This builds on the BRAINS grant received by GliaPharm to advance understanding of glia-mediated pathways.
- Wyss Center for Bio and NeuroengineeringmajorCollaboration with the Wyss Center, a non-profit organization in Geneva focused on advancing bioengineering and neurotechnology research.
- HEPIAminorCollaboration with HEPIA to setup a new 3D culture method using brain organoids from mouse and human-derived cells, expanding GliaPharm's GliaX™ platform capabilities.
- UCBmajorStrategic collaboration announced in October 2022 between GliaPharm and UCB focused on developing treatments for neurological disorders targeting glial cell pathways.
- TRB ChemedicaminorListed as a partner on the GliaPharm partners page. TRB Chemedica is a pharmaceutical company focused on respiratory and neurological conditions.
- Campus BiotechcoreGliaPharm is located at Campus Biotech in Geneva, a leading life sciences campus bringing together biotech companies, academic institutions, and research centers.
- EPFL (Ecole Polytechnique Fédérale de Lausanne)coreGliaPharm originated as a spinoff from Prof. Magistretti's laboratory at EPFL, where the foundational research on the Astrocyte-Neuron Lactate Shuttle was conducted over three decades.
- University of Lausanne (UNIL)majorAcademic partner in neurological disease research collaboration. UNIL researchers contribute to understanding glial cell biology and brain metabolism.
- University of BernmajorAcademic partner in the Innosuisse-supported project for developing cell therapy to treat neurological diseases.
- FoxG1 Research FoundationminorPartner foundation focused on FOXG1 syndrome research, a neurodevelopmental disorder potentially involving glial cell dysfunction.
- Black Swan FoundationminorSwiss foundation supporting research in neurological conditions.
- CIBM (Center for Biomedical Imaging)minorSwiss center for biomedical imaging research providing imaging infrastructure and expertise supporting GliaPharm's brain metabolism research.
Scale indicators1 record
Recent moves8 records
Expansion highlights5 records
GliaPharm competitors and assessment
Company assessmentDirect peers
- AC Immune: Swiss clinical-stage biopharmaceutical company focused on Alzheimer's disease and neurodegenerative disorders. Directly comparable as a Switzerland-based, CNS-focused biotech pursuing novel disease-modifying mechanisms at similar development stage.
- Alector: Clinical-stage biotechnology company developing therapies for neurodegenerative diseases by targeting immune cells in the brain (microglia). Highly comparable mechanism philosophy — leveraging brain-resident non-neuronal cells to treat CNS disorders.
- Idorsia: Swiss specialty pharmaceutical company focused on CNS and other therapeutic areas. Comparable as a Swiss-headquartered CNS-focused drug developer with neuroscience pipeline assets across multiple indications.
- Denali Therapeutics: Clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases. Comparable mission, target indications (Alzheimer's, ALS), and focus on brain biology-driven drug discovery.
- Sage Therapeutics: Clinical-stage biopharmaceutical company developing CNS medicines, including depression and neurological indications. Comparable as a CNS-focused biotech pursuing differentiated mechanisms in depression and neurology.
- Cassava Sciences: Clinical-stage biopharmaceutical company focused on Alzheimer's disease. Comparable as a small-cap, single-indication-focused Alzheimer's biotech advancing novel CNS mechanisms toward clinical proof-of-concept.
Broad incumbents
- UCB: Global biopharmaceutical company with a major CNS franchise (epilepsy, Parkinson's). Listed here both as GliaPharm's strategic collaborator and as a larger incumbent in the same CNS drug-development space.
- Lundbeck: Global pharmaceutical company specialized in psychiatric and neurological disorders. Comparable as an established CNS specialty pharma and a likely strategic acquirer/partner for CNS-focused biotechs.
- Biogen: Major biopharmaceutical company with a leadership position in neurodegenerative diseases (Alzheimer's, ALS). Comparable as a large incumbent pursuing the same high-unmet-need CNS indications GliaPharm targets.
- Eli Lilly: Global pharmaceutical company with a significant Alzheimer's disease program (including recently approved amyloid-targeting therapy). Comparable as a well-capitalized incumbent competing in the same Alzheimer's indication GliaPharm is pursuing.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
GliaPharm social profiles
Digital presenceGliaPharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
GliaPharm leadership team
Management profileNumber of profiles
Profiles5 records
GliaPharm funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GliaPharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GliaPharm
What does GliaPharm do?
GliaPharm is a clinical-stage biopharmaceutical company that discovers and develops novel drugs targeting glial cell pathways — specifically astrocytes and the Astrocyte-Neuron Lactate Shuttle (ANLS) — to treat neurological and psychiatric disorders characterized by deficient brain energy metabolism. Its lead drug candidate GP-119 is being advanced through IND-enabling studies for Alzheimer's disease, while its proprietary GliaX™ drug discovery platform identifies additional molecular targets and drug candidates across Alzheimer's, GLUT1 deficiency syndrome, ALS, and major depression.
Is GliaPharm a public or private company?
GliaPharm is a private company. It is classified as venture growth investor backed and is currently operating.
When was GliaPharm founded?
GliaPharm was founded in 2016. It employs 1 to 10 people.
Where is GliaPharm based?
GliaPharm is headquartered in Geneva, Switzerland, in the Europe region.
How does GliaPharm make money?
One revenue line is on record: drug Development & Licensing.
Who are GliaPharm's main competitors?
Direct peers on record are AC Immune, Alector, Idorsia, Denali Therapeutics, Sage Therapeutics and Cassava Sciences. Broad incumbents are UCB, Lundbeck, Biogen and Eli Lilly.
Does GliaPharm have an API?
No public API is recorded for GliaPharm.
What industry is GliaPharm in?
GliaPharm's product category is Biopharmaceuticals — CNS / Neurology Drug Discovery. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.